CD274 and breast carcinoma: We characterized [89Zr]-Atezolizumab in vitro and in vivo using imaging studies and demonstrated its potential to assess changes in PD-L1 expression following cytotoxic treatment in patient-derived xenografts, which better recapitulates the clinical heterogeneity of the disease and is a clinically relevant model of breast cancer.